Differential effects in humans after repeated administrations of zolpidem and triazolam

American Journal of Drug and Alcohol Abuse

Volumn 29, Issue 2, 2003, Pages 281-299

  Stoops, William W ^a   Rush, Craig R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Humans; Tolerance; Triazolam; Zolpidem

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE; BENZODIAZEPINE RECEPTOR; HYPNOTIC SEDATIVE AGENT; LACTULOSE; PLACEBO; RECEPTOR SUBTYPE; TRIAZOLAM; ZOLPIDEM TARTRATE;

ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG TOLERANCE; HUMAN; PSYCHOMETRY; QUESTIONNAIRE; RATING SCALE; RECALL; SEDATION; TASK PERFORMANCE;

ADULT; FEMALE; GABA AGONISTS; GABA MODULATORS; HUMANS; MALE; MEMORY; MENTAL RECALL; PSYCHOMOTOR PERFORMANCE; PYRIDINES; QUESTIONNAIRES; TIME FACTORS; TRIAZOLAM;

EID: 0037609710     PISSN: 00952990     EISSN: None     Source Type: Journal    
DOI: 10.1081/ADA-120020513     Document Type: Article

References (46)

1. Hollister LE, Muller-Oerlinghausen B, Rickels K, Shader RI. Clinical uses of benzodiazepines. J Clin Psychopharmacol 1993; 23:1S-169S.
2. Cole SO. Effects of benzodiazepines on acquisition and performance: a critical assessment. Neurosci Biobehav Rev 1986; 10:265-272.
3. Curran HV. Benzodiazepines, memory and mood: a review. Psychopharmacology (Berl) 1991; 105:1-8.
4. Ghoneim MM, Mewaldt SP. Benzodiazepines and human memory: a review. Anesthesiology 1990; 72:926-938.
5. Lister RG. The amnestic action of benzodiazepines in man. Neurosci Biobehav Rev 1985; 9:87-94.
6. Roth T, Roehrs TA. A review of the safety profiles of benzodiazepine hypnotics. J Clin Psychiatry 1991; 52:38-41.
7. Woods JH, Katz JL, Winger G. Abuse liability of benzodiazepines. Pharmacol Rev 1987; 39:251-413.
8. Woods JH, Katz JL, Winger G. Benzodiazepines: use abuse, and consequences. Pharmacol Rev 1992; 44:151-347.
9. Chodera A, Nowakowska E, Bartczak G. Tolerance to a new class of non-benzodiazepine anxiolytics. Pol J Pharmacol 1994; 46:479-481.
10. Cardinale V. Drug Topics Redbook. Montvale, NJ: Medical Economics, 1996.
11. Haefely WE. Pharmacology of the benzodiazepine receptor. Eur Arch Psychiatr Neurol Sci 1989; 238:294-301.
12. Sanger DJ, Morel E, Perrault G. Comparison of the pharmacological profiles of the hypnotic drugs zaleplon and zolpidem. Eur J Pharmacol 1996; 313:35-42.
13. Sauvanet JP, Langer SZ, Morselli PL. Imidazopyridines in sleep disorders. New York: Raven Press, 1988.
14. a Receptor subtypes and the mechanism of action in zolpidem. In: Freeman H, Puech AJ, Roth T, eds. Zolpidem: An Update of Its Pharmacological Properties and Therapeutic Place in the Management of Insomnia. Paris: Elsevier, 1996:21-32.
15. Cox A, Boyland P, Gent JP, Feely M. An investigation of anticonvulsant tolerance to zolpidem I mice. Br J Pharmacol 1988; 95:667P.
16. Elliott EE, White JM. Precipitated and spontaneous withdrawal following administration of lorazepam but not zolpidem. Pharmacol Biochem Behav 2000; 66:361-369.
17. Perrault G, Morel E, Sanger DJ, Zivkovic B. Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem. J Pharmacol Exp Ther 1992; 263:298-303.
18. Sanger DJ, Zivkovic B. Investigation of the development of tolerance to the actions of zolpidem and midazolam. Neuropharmacology 1987; 26:1513-1518.
19. a receptors. Neuropharmacology 1992; 31:693-700.
20. Griffiths RR, Sannerud CA, Ator NA, Brady JV. Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance, and withdrawal. J Pharmacol Exp Ther 1992; 260:1199-1208.
21. Sannerud CA, Cook JM, Griffiths RR. Behavioral differentiation of benzodiazepine ligands after repeated administration in baboons. Eur J Pharmacol 1989; 167:333-343.
22. Soldatos CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol 1999; 14:287-303.
23. Ware JC, Walsh JK, Scharf MB, Roehrs T, Roth T, Vogel GW. Minimal rebound insomnia after treatment with 10 mg zolpidem. Clin Neuropharmacol 1997; 20:116-125.
24. Evans SM, Funderburk FR, Griffiths RR. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 1990; 255:1246-1255.
25. Griffiths RR, Bigelow GE, Liebson I. Differential effects of diazepam and pentobarbital on mood and behavior. Arch Gen Psychiatry 1983; 40:865-873.
26. Oliveto AH, Bickel WK, Hughes JR, Shea PJ, Higgins ST, Fenwick JW. Caffeine drug discrimination in humans: acquisition, specifications, and correlation with self-reports. J Pharmacol Exp Ther 1992; 261:885-894.
27. Rush CR, Baker RW, Rowlett JK. Discriminative-stimulus effects of zolpidem, triazolam, pentobarbital, and caffeine in zolpidem-trained humans. Exp Clin Psychopharmacol 2000; 8:22-36.
28. Kollins SH, Rush CR. Sensitization to the cardiovascular but not subject-rated effects of oral cocaine in humans. Biol Psychiatry 2002; 51:143-150,
29. Singha AK, McCance-Katz EF, Petrakis I, Kosten TR, Oliveto A. Sex differences in self-reported and physiological response to oral cocaine and placebo in humans. Am J Drug Alcohol Abuse 2000; 26:643-657.
30. Zacny JP. Morphine responses in humans: a retrospective analysis of sex differences. Drug Alcohol Depend 2001; 63:23-28.
31. Rush CR, Kelly TH, Fillmore MT, Hays LR. Discriminative-stimulus and subject-rated effects of triazolam in light versus moderate drinkers: a dose-response analysis, Under Review.
32. Mumford GK, Rush CR, Griffiths RR. Abecarnil and alprazolam in humans: behavioral, subjective, and reinforcing effects. J Pharmacol Exp Ther 1995; 272:570-580.
33. McLeod DR, Griffiths RR, Bigelow GE, Yingling JE. An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instrum 1982; 14:463-466.
34. Jasinski D. Assessment of the abuse potentiality of morphine like drugs (methods used in man). In: Martin WR, ed. Drug Addiction I. New York: Springer-Verlag, 1977:197-258.
35. Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971; 12:245-258.
36. Abreu ME, Griffiths RR. Drug tasting may confound human drug discrimination studies. Psychopharmacol (Berl) 1996; 125:255-257.
37. Fairweather DB, Kerr JS, Hindmarch I. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Clin Pharmacol 1992; 43:597-601.
38. Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL. Zolpidem and rebound insomnia - a double-blind, controlled polysomnographic study in chronic insomnia patients. Pharmacopsychiatry 1994; 27:166-175.
39. Poirrier R, Franck G, Scheldewaert R, Jolie A, Tomas M. The effect of long-term zolpidem treatment on nocturnal polysomnography and daytime vigilance in patients with psychophysiological insomnia. Acta Ther 1994; 20:77-86.
40. Roger M, Attali P, Coquelin JP. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin Ther 1993; 15:127-136.
41. Scharf MB, Roth T, Vogel GW, Walsh JK. A multi-center, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994; 55:192-199.
42. Schlich D, Heritier CL, Coquelin JP, Attali P. Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res 1991; 19:271-279.
43. Shaw SH, Curson H, Coquelin JP. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric inpatients. Int J Med Res 1992; 20:150-161.
44. Schuster CR, Johanson CE. Relationship between the discriminative stimulus properties and subjective effects of drugs. In: Colpaert FC, Balster RL, eds. Transduction Mechanisms of Drug Stimuli. Berlin: Springer, 1988:161-175.
45. Pugh SL, Boone MS, Emmett-Oglesby MW. Tolerance, cross-tolerance, and withdrawal in rats made dependent on diazepam. J Pharmacol Exp Ther 1992; 262:751-758.
46. Roache JD, Griffiths RR. Comparison of triazolam and pentobarbital: performance impairment, subjective effects and abuse liability. J Pharmacol Exp Ther 1985; 234:120-133.